---
title: "Arrow Pharmaceuticals soars 22% on strong Phase 3 lipid drug results"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293511229.md"
description: "Arrow Pharma jumps 22% as Phase 3 data shows 79-81% triglyceride drop; FDA filing planned for late 2026."
datetime: "2026-07-22T19:13:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293511229.md)
  - [en](https://longbridge.com/en/news/293511229.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293511229.md)
---

# Arrow Pharmaceuticals soars 22% on strong Phase 3 lipid drug results

箭头制药 (ARWR.US) 盘中涨**21.85%**，现报**90.80 美元**。

plozasiran 降脂药三期试验显示强效，甘油三酯水平降低 79-81%，安全性良好。公司计划 2026 年底向 FDA 提交补充新药申请。

### Related Stocks

- [ARWR.US](https://longbridge.com/en/quote/ARWR.US.md)

## Related News & Research

- [The Bull Case For Arrowhead Pharmaceuticals (ARWR) Could Change Following Plozasiran’s Phase 3 Success And Zodasiran Milestone](https://longbridge.com/en/news/294635779.md)
- [Arrowhead Drug Shows Strong Efficacy In Cutting Blood Fat](https://longbridge.com/en/news/293509194.md)
- [Tarsus Pharmaceuticals (TARS) Could Be 38% Undervalued Following Cautious Earnings Expectations](https://longbridge.com/en/news/294318126.md)
- [Healthcare of Ontario Pension Plan Trust Fund Invests $16.49 Million in Axsome Therapeutics, Inc. $AXSM](https://longbridge.com/en/news/294039544.md)
- [GH Research (GHRS) to Announce Earnings on Thursday](https://longbridge.com/en/news/294319262.md)